Psoriatic Arthritis

The diagnosis and management of psoriatic arthritis (PsA) can be challenging. It is important to make the right diagnosis and to start treating PsA early to optimize outcomes and to reduce the social and economic burden of this disease.
The method used to administer medication to patients can also heavily impact their medication adherence, placing a lot of importance on the quality and clinical relevance of adherence measures.
Sixteen experts from across Europe and the United States have issued a series of recommendations based on a Psoriatic Arthritis Forum consensus meeting held in October 2013.
Brodalumab improved the signs and symptoms of psoriatic arthritis (PsA) at week 12, week 24, and week 52, according to results of a phase 2 trial and an open-label extension of that trial.
Toronto, ON—The results of a study on new-onset psoriatic arthritis (PsA) underline the importance of attention to warning signs in order to achieve early referral of patients to rheumatologists. The study showed that the risk for PsA, which is a relatively common condition, is highest in individuals with a higher Psoriasis Area and Severity Index (PASI) score, nail involvement, and a higher body mass index (BMI).
Limited data exist on the validity of diagnostic codes for psoriasis and psoriatic arthritis (PsA). A group of researcher from Sweden recently evaluated the validity of the International Classification of Diseases, Tenth Revision Systematisk Förtecking (ICD-10-SE) for both disorders in the Skåne Healthcare Register (SHR), and found that SHR was a valid healthcare register for studies on psoriasis and PsA.
Infections may be associated with comorbidity and mortality in patients with psoriatic arthritis (PA) and ankylosing spondylitis (AS; spondyloarthropathy [SpA]), and rheumatoid arthritis (RA). Results from a retrospective observational study suggest that anti–tumor necrosis factor; (TNF)-alpha and corticosteroids (CS) combination promote infection; disease-modifying antirheumatic drugs (DMARDs) were found to be relatively safe.
By Wayne Kuznar San Diego, CA—Brodalumab, a mono­clonal antibody to the interleukin (IL)-17 receptor A, is associated with significant clinical response and an acceptable safety profile in patients with psoriatic arthritis (PsA), said Mark C. Genovese, MD, Professor of Medicine, Immunology and Rheumatology, Stanford University, Palo Alto, CA, at the 2013 American College of Rheumatology (ACR) meeting.
The manufacturers of the first and only multibiomarkerbased blood test validated to monitor disease activity in patients with rheumatoid arthritis (RA), Crescendo Bioscience, Inc, is in the process of being acquired by Myriad Genetics, Inc. Vectra DA is a quantitative, protein-based test that allows for routine monitoring of disease activity and allows rheumatologists to more effectively treat their patients.
By Phoebe Starr San Diego, CA—Using a “treat-to-target” strategy (ie, tight control) was superior to the standard approach in reducing disease activity in the skin and joints of patients with newly diagnosed psoriatic arthritis in the randomized Tight Control of Psoriatic Arthritis (TICOPA) trial. Treat to target has been successful in controlling disease activity in patients with rheumatoid arthritis, and TICOPA provides evidence in support of this approach in psoriatic arthritis.
Page 2 of 4
Results 11 - 20 of 32
  • Rheumatology Practice Management
  • Lynx CME
  • American Health & Drug Benefits
  • Value-Based Cancer Care
  • Value-Based Care in Myeloma
  • Value-Based Care in Neurology